RxDoctor Payments Data

John Yaft, MD

Internal Medicine · Irving, TXNPI 1104147982

Payments from drug & device makers

$3,375in general payments, 2019–2025

Across 60 payments — averaging $56.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • AstraZeneca$660
  • Merck$238
  • Pfizer$228
  • Chiesi USA, Inc.$164
  • Cumberland Pharmaceuticals, Inc.$152
  • plus $342 from 9 others

What the payments were for

  • Consulting fees$1,59047%
  • Food & beverage$1,78453%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,375 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,850
Medicare patients
59
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$44,337
JardianceEmpagliflozin47$13,391
NamzaricMemantine Hcl/Donepezil Hcl16$4,706
Budesonide15$3,198
Atorvastatin Calcium144$2,203
Mirtazapine59$2,086
Gabapentin70$1,208
Furosemide109$1,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,072
Metoprolol Succinate49$1,023
Tamsulosin Hcl50$990
Buspirone Hcl36$964
Carbidopa-LevodopaCarbidopa/Levodopa20$903
Levothyroxine Sodium73$893
Duloxetine Hcl39$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$44,337166 claims
Boehringer IngelheimJardiance$1,590$13,39147 claims
AbbVieNamzaric$52$4,70616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →